ZDHHC18 polyclonal antibody
- Known as:
- ZDHHC18 pab (anti-)
- Catalog number:
- PAB23641
- Product Quantity:
- 100 uL
- Category:
- -
- Supplier:
- Abno
- Gene target:
- ZDHHC18 polyclonal antibody
Related genes to: ZDHHC18 polyclonal antibody
- Gene:
- ZDHHC18 NIH gene
- Name:
- zinc finger DHHC-type containing 18
- Previous symbol:
- -
- Synonyms:
- DKFZp667O2416
- Chromosome:
- 1p36.11
- Locus Type:
- gene with protein product
- Date approved:
- 2003-03-21
- Date modifiied:
- 2016-02-15
Related products to: ZDHHC18 polyclonal antibody
Related articles to: ZDHHC18 polyclonal antibody
- SARS-CoV-2 accessory protein ORF3a contributes to viral pathogenesis through membrane remodeling, immune evasion, and inflammation induction. However, the molecular mechanisms underlying ORF3a-mediated pathogenesis remain poorly characterized, and no therapeutic strategies targeting ORF3a currently exist. Here, we demonstrate that palmitoylation, a post-translational modification, governs ORF3a-mediated viral pathogenesis. Specifically, ORF3a undergoes ZDHHC18-mediated palmitoylation at evolutionarily conserved Cys130/Cys133 residues, which stabilizes the protein by masking an intrinsic proteasomal degradation signal. This palmitoylation competitively inhibits tripartite motif-containing 16 (TRIM16)-dependent K27-linked polyubiquitination, thereby preventing ORF3a degradation and enhancing viral replication and inflammatory responses. A designed ORF3a-mimicking palmitoylation-inhibitory peptide (OPIP) blocked ORF3a palmitoylation, promoted its degradation, and significantly reduced SARS-CoV-2 pathogenicity. Collectively, these findings establish ZDHHC18-mediated palmitoylation as a central regulator of ORF3a stability and virulence, revealing a potentially druggable axis for disrupting SARS-CoV-2 pathogenesis. - Source: PubMed
Publication date: 2026/05/10
Yang SidiLi KunLiu LihongZeng LinsenDeng QifengHuang JiachengDong XiaoranWang XinLiang JianweiLiu HongchaoPeng HongLin YuxinXie XiaoluYe YuzhenXu TiefengWang ZhaohuanLi Chun-MeiGuo Deyin - Although the acylation modification (AM) significantly influences the development of lung adenocarcinoma (LUAD), the specific mechanisms of acylation modification in this context have not been widely researched. This investigation sought to discover novel therapeutic avenues related to acylation modification for the precision treatment of LUAD. - Source: PubMed
Publication date: 2026/04/07
Xiao QifanBu JianlongLiu MengfengShi LeiQu Changfa - Protein palmitoylation, a key posttranslational modification, is involved in cell signaling, protein stability, and tumor immune microenvironment (TIME) regulation. ZDHHC3 is known to mediate clear cell renal cell carcinoma (ccRCC) immune evasion by enhancing PD-L1 stability, but the roles of other palmitoyltransferases in ccRCC remain unclear. In this study, we analyzed genomic and transcriptomic data via a multiomics approach to investigate the expression patterns and potential regulatory mechanisms of known palmitoylation enzymes in ccRCC. - Source: PubMed
Publication date: 2026/03/06
Guo ABaoLu YaoWang JunJia ZhanKuiYang JinJianNing Xianghui - Clear cell renal cell carcinoma (ccRCC) is a highly aggressive cancer with a poor prognosis. Palmitoylation, a posttranslational modification, plays a key role in regulating cancer progression and immune responses. However, its influence on ccRCC prognosis and immune therapy efficacy remains underexplored. - Source: PubMed
Publication date: 2025/11/29
Zhang DongZhang KeDeng MinghaoMa JiakangZhu JianShen ShuijieXie JianjunChen Chao - This work sought to examine the causal link between palmoyl-protein-modifying genes (ZDHHC family) and epilepsy by Mendelian randomisation (MR), utilising multi-level genomic data. A two-sample MR analysis was performed utilising publicly accessible blood and brain tissue expression quantitative trait locus (eQTL) data as exposure variables and epilepsy genome-wide association study (GWAS) data from the FinnGen as the outcome measure. The major analysis method utilised was inverse variance weighting (IVW), with robustness validation conducted by weighted median and MR-Egger procedures. Subsequently, summary-data-based MR (SMR) analysis confirmed signal colocalization, supplemented by single-cell transcriptomic data (GSE302285) to investigate target gene expression patterns at a cellular granularity. MR analysis indicated that heightened expression of ZDHHC3 (OR = 0.69, 95% CI: 0.57-0.84, p = 0.0002) and ZDHHC20 (OR = 0.88, 95% CI: 0.82-0.94, p = 0.0002) was significantly linked to a decreased risk of epilepsy, while increased expression of ZDHHC8 and ZDHHC18 was associated with an elevated risk. SMR analysis further corroborated the protective roles of ZDHHC3 and ZDHHC20. Layered MR analysis showed that the results are more significant in focal epilepsy. An eQTL study specific to brain cells revealed cell-type specificity in these correlations, with ZDHHC20 demonstrating the most significant protective impact in excitatory neurones (OR = 0.89, p = 0.0273). Single-cell transcriptomics demonstrated that ZDHHC20 was significantly expressed in astrocytes and neurones in the brain tissue of epilepsy patients, while ZDHHC3 was primarily concentrated in neurones. This work genetically confirms that certain palmitoylation genes, notably ZDHHC3 and ZDHHC20, may have causative protective effects against the risk of focal epilepsy, highlighting cell-type-specific processes. This establishes innovative theoretical frameworks for exploring the pathophysiology of epilepsy and formulating targeted treatments. - Source: PubMed
Publication date: 2025/10/16
Qiu JinXian DehaiYang Kaiwen